The covalent attachment of SUMO (small ubiquitin-like protein modifier) to target proteins results in modifications in their activity, binding interactions, localization or half-life. The reversal of this modification is catalysed by SENPs (SUMO-specific processing proteases). Mammals contain four SUMO paralogues and six SENP enzymes. In the present paper, we describe a systematic analysis of human SENPs, integrating estimates of relative selectivity for SUMO1 and SUMO2, and kinetic measurements of recombinant C-terminal cSENPs (SENP catalytic domains). We first characterized the reaction of each endogenous SENP and cSENPs with HA-SUMO-VS [HA (haemagglutinin)-tagged SUMO-vinyl sulfones], activesite-directed irreversible inhibitors of SENPs. We found that all cSENPs and endogenous SENP1 react with both SUMO paralogues, whereas all other endogeneous SENPs in mammalian cells and tissues display high selectivity for SUMO2-VS. To obtain more quantitative data, the kinetic properties of purified cSENPs were determined using SUMO1-or SUMO2-AMC (7-amino-4-methylcoumarin) as substrate. All enzymes bind their respective substrates with high affinity. cSENP1 and cSENP2 process either SUMO substrate with similar affinity and catalytic efficiency; cSENP5 and cSENP6 show marked catalytic specificity for SUMO2 as measured by K m and k cat , whereas cSENP7 works only on SUMO2. Compared with cSENPs, recombinant full-length SENP1 and SENP2 show differences in SUMO selectivity, indicating that paralogue specificity is influenced by the presence of the variable N-terminal domain of each SENP. Our data suggest that SUMO2 metabolism is more dynamic than that of SUMO1 since most SENPs display a marked preference for SUMO2.
INTRODUCTION
SUMO (small ubiquitin-like protein modifier) family proteins share a conserved ubiquitin-like domain and a C-terminal di-glycine motif. The covalent modification of proteins by SUMO plays a dynamic role in transcriptional regulation, formation of PML (promyelocytic leukaemia) nuclear bodies, nuclear transport, chromosome organization, DNA repair, mitotic progression and ribosome biogenesis [1] [2] [3] [4] .
Whereas Saccharomyces cerevisiae, Caenorhabditis elegans and Drosophila melanogaster have a single SUMO, humans have four SUMO paralogues. Human SUMO2 and SUMO3 are well conserved and share 95 % amino acid sequence identity. A key property of SUMO2 and SUMO3 is their ability to polymerize and form poly-SUMO chains [5] . SUMO4, another isoform, has been found to be 86 % identical with SUMO2 and SUMO3 [6] . However, it has a very restricted tissue distribution and has not yet been shown to modify target proteins in vivo. SUMO1 is the most divergent family member, sharing 46 % identity with SUMO2 and SUMO3.
Recent proteomic studies have identified many proteins modified by SUMO [7] [8] [9] [10] [11] . The best-studied are RanGAP1 (Ran GTP-activating protein 1) and topoisomerase II, predominantly modified by SUMO1 and SUMO2/3 respectively [12, 13] . Many SUMO-conjugated proteins are found in the nucleus, suggesting that SUMOylation is an important nuclear process [14] . In fact, SUMO2 and SUMO3 locate to the nucleoplasm, whereas SUMO1 is distributed to the nuclear envelope and the nucleolus [15] .
The covalent addition of SUMO to a target protein (SUMOylation) forms an isopeptide bond between the C-terminus of mature SUMO and the ε-amino group of the target lysine residue in the substrate protein. SUMOylation is catalysed by a specific SUMO-E1 activating enzyme, the heterodimeric SAE1-SAE2, one SUMO-E2 conjugating enzyme, Ubc9, and various SUMO-E3 ligases (Pc2, Siz1, RanBP2/Nup358, etc.). This is a reversible modification regulated by both SUMOylating and deSUMOylating enzymes [SENPs (SUMO-specific processing proteases)]. SENPs also have an endopeptidase (C-terminal hydrolase) activity that is essential to process SUMO precursor proteins to expose the C-terminal di-glycine motif and yield mature SUMO.
Six SUMO-specific SENPs have been identified in humans, SENPs 1, 2, 3, 5, 6 and 7. Most SENPs possess both isopeptidase and endopeptidase activity, and it is not yet clear which activity is most essential for each SENP [16] . Evolutionary relationships divide SENPs into two major groups: the Ulp1p group (consisting of two subfamilies: SENP1 and SENP2, and SENP3 and SENP5) and the Ulp2p group (SENP6 and SENP7) [17] . These genetic distinctions are also reflected in the specificity of the enzymes ( [18, 19] , the present study); SENP1 and 2 catalyse hydrolysis of both SUMO1 and SUMO2/3 derivatives [20, 21] , SENP3 and SENP5 prefer SUMO2/3 [22] , and SENP6 and SENP7 are thought to work best on poly-SUMO2/3 [23, 24] . A seventh Ulp family protease, SENP8 (also known as Den1 or NEDP1), shares marked similarity in the SENP catalytic domain, but lacks a SUMO-binding site and instead shows specificity for NEDD8 (neural-precursor-cell-expressed developmentally downregulated 8) [25] [26] [27] [28] .
SENPs share a conserved C-terminal cysteine protease domain of approx. 250 amino acids containing the catalytic triad HisAsp-Cys ( Figure 1 ). The SENP N-terminal domain is not well conserved and, although there are essentially no data on this domain, it is believed to be responsible for substrate specificity and/or localization [29] . The SENP N-terminal domains vary in primary sequence and size [30] . SENP1 and SENP2 have NLSs (nuclear localization signals) and NESs (nuclear export signals) that probably play a role in the regulation of cellular localization, along with other potential regulatory motifs which vary for each individual SENP [29] . SENP1 localizes to the nuclear foci and the nuclear rim [31] . SENP2 exists in three splice variants that localize differently: SENP2/Axam to the nuclear side of the nuclear pore complex [32, 33] ; Smt3IP2/Axam2 to the cytoplasm [34] ; and SuPr-1 to PML oncogenic domains [35] . Both SENP3 and SENP5 localize to the nucleolus [22, 36] , whereas SENP6 and SENP7 are both found in the nucleoplasm [23, 24, 37] .
Previous studies indicate that SENPs might be highly targetspecific and non-redundant in vivo. SENP1, SENP2 and SENP3 function by modulating nucleocytoplasmic shuttling [38] [39] [40] . SENP1 and SENP2/SuPr-1 regulate c-Jun-dependent transcription [35, 41] . SENP5 plays a physiological role in cell division and cell proliferation [42] . Both SENP3 and SENP5 interact with B23/nucleophosmin in vivo to promote ribosome synthesis [4, 43] , whereas SENP6 and SENP7 appear to regulate PML metabolism in vivo [23, 24] . Thus substrate specificity is a consequence of SENP expression levels, the localization or co-localization with substrates and their inherent capability to distinguish different SUMO paralogues. Nonetheless, the functional role of different SENPs in cellular processes is still poorly understood.
In the present study, we have concentrated on characterizing the paralogue selectivity of mammalian SENPs. HA-SUMO-VS [HA (haemagglutinin)-tagged SUMO-vinyl sulfones] were used as active-site-directed irreversible inhibitors to identify binding and catalytic preference of SENPs for SUMO1 or SUMO2. Additionally, AMC (7-amino-4-methylcoumarin) derivatives of SUMO were used as substrates to determine SENP isopeptidase activity and catalytic specificity. We examined both full-length endogenous SENPs in lysates to identify isoform selectivity and recombinant C-terminal catalytic domains to measure and compare catalytic constants. Whereas all recombinant cSENPs (SENP catalytic domains) react with either SUMO-VS paralogue, endogenous SENPs 2, 3, 5, 6 and 7 show distinct preferential selectivity for SUMO2 over SUMO1. We also observed that the non-conserved N-terminal domain of SENP2 plays a significant role in SENP selectivity.
EXPERIMENTAL Preparation of VS and AMC reagents
HA-SUMO1-VS, HA-SUMO2-VS, SUMO1-AMC and SUMO2-AMC were prepared using intein fusion protein technology as detailed previously [44] . SUMO1 and SUMO2 expression, purification and concentration was monitored by SDS/PAGE analysis (12 % gels) and HPLC on a C 8 reverse-phase column (buffer A was 25 mM NaClO 4 and 0.07 % HClO 4 , and buffer B was buffer A plus 75 % acetonitrile with a 0-80 % gradient over 25 min, monitoring the absorbance at 205 nm). MALDI (matrix-assisted laser-desorption ionization)-MS analysis confirmed the purity and identity of the VS and AMC derivatives. All masses were consistent with the expected mass within + − 0.1 %.
Protein expression and purification
Full-length pGEX-Ulp1 and pGEX-Ulp1 403−621 were expressed in BL21 cells induced with 0.5 mM IPTG (isopropyl β-Dthiogalactopyranoside) during a 3 h induction at room temperature (25 • C). Expressed pGEX-Ulp1 protein was isolated with glutathione-agarose resin (Sigma) and pGEX-Ulp1 403−621 on Ni-NTA (Ni 2+ -nitrilotriacetate)-agarose (Invitrogen) respectively. The recombinant catalytic domains of SENPs 1, 2, 3, 5, 6 and 7 and His 6 -tagged full-length SENP1 and SENP2 were expressed in Escherichia coli and purified as described previously [16] . Purification of all proteins was evaluated by SDS/PAGE (12 % gel).
Mammalian cell lysates and rabbit tissue extracts
HEK (human embryonic kidney)-293, HeLa, LM TK − , A9 and Cos-7 cells were grown in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) fetal bovine serum and antibiotics at 37
• C in a 5% CO 2 incubator. Cells were lysed by sonication in lysis buffer (50 mM Tris/HCl, pH 7.4, 5 mM MgCl 2 , 250 mM sucrose, 1 mM dithiothreitol and 2 mM ATP) with protease inhibitors (Roche Diagnostics). The cell lysates were clarified by centrifugation at 16 500 rev./min for 30 min using a Beckman Ti-70 rotor. Rabbit thymus, spleen, brain, heart, adrenal and thyroid gland (Pel freeze) were homogenized in lysis buffer with protease inhibitors. Extracts were clarified initially by centrifugation at 16 500 rev./min for 15 min followed by 22 000 rev./min for 1 h using a Beckman Ti-70 rotor.
Steady-state kinetic analysis
Enzyme activity assays for cSENPs and cell lysates were performed as described previously [45] using a SUMO C-terminal AMC substrate [44] . In a typical assay, 140 μl of assay buffer (50 mM Tris/HCl, pH 7.8, 100 μg/ml ovalbumin and 10 mM dithiothreitol) containing various concentrations of SUMO1-AMC or SUMO2-AMC and purified cSENPs were added to the reaction mixture. The reaction was monitored by measuring the increase in fluorescence at 440 nm (λ ex = 340 nm) using an Aminco Bowman Series 2 fluorimeter. Activity assays were conducted at 37
• C in triplicate. The SUMO-AMC preparations contained approx. 10 % unlabelled SUMO (results not shown). The simplest model of Michaelis and Menten was used to fit the rate of enzyme activity as a function of substrate concentration. The initial rates obtained with each enzyme were compared and the apparent K m and K i values for each substrate were determined. For K i measurements, substrate was kept constant at levels below the apparent K m , and rates were determined in the presence of free SUMO paralogues as inhibitors. Data were fitted to the following equation to estimate kinetic constants:
For K m measurements, minor adjustments had to be made for the fact that there was a small amount of SUMO present in the substrate (∼ 10 %). Thus data were fitted to the following equation (where F = 0.10). Reactions were monitored using Covance mouse anti-HA.11 monoclonal antibody in Western blocking buffer [1 × TBS (Trisbuffered saline), 0.05 % Tween 20 and 5 % (w/v) non-fat dried milk powder]. Polyclonal antibodies against SENPs were raised in rabbit and affinity-purified on immobilized antigen [4, 23] . Each SENP was detected in immunoblots using anti-SENP1 (fulllength protein), anti-SENP2 (full-length protein), anti-SENP3 (residues 204-406 [4, 23] ), anti-SENP5 (residues 1-237 [4, 23] ), anti-SENP6 (residues 1-499 [4, 23] ) and anti-SENP7 (full-length protein) were used to detect each SENP. Secondary antibodies were HRP (horseradish peroxidase)-conjugated anti-mouse IgG or HRP-conjugated anti-rabbit IgG as required, and antibodies were detected by the ECL (enhanced chemiluminescence) detection system (Amersham Biosciences).
RESULTS
Most studies suggest that different SENP enzymes exhibit different affinities and various degrees of selectivity for SUMO paralogues, although no comprehensive studies have examined all SENPs in a quantitative way. To compare and understand differences between SUMO proteases, we synthesized HA-SUMO-VS [4, 23, 46, 47] and SUMO-AMC. These reagents are specific for deSUMOylating enzymes [44] and thus appropriate to be used in quantitative studies to characterize the catalytic capability and specificity of human full-length SENPs and cSENPs acting on SUMO1 and SUMO2. We first examined the catalytic capability of the core catalytic domains to ascertain the range of possible substrates. Since these studies were carried out in the absence of other cellular components and on proteins that lack the physiological N-terminal domain, we also characterized the full-length endogenous SENPs in mammalian tissues and cell lysates.
Irreversible labelling of the catalytic domains of SENPs with HA-SUMO-VS
Six human SENPs (1, 2, 3, 5, 6 and 7) have been identified in genomic databases and structural analysis has revealed that they are cysteine proteases. They all contain a conserved C-terminal catalytic domain and a variable N-terminal domain. (Figure 1 ). The non-conserved N-terminal regions are thought to determine subcellular localization and paralogue specificity. In addition, SENP6 and SENP7 have small sequence inserts in their catalytic domain.
To determine the SUMO paralogue preferences of the catalytic domain of SENPs, we expressed cSENPs 1, 2, 5, 6 and 7 in E. coli with an N-terminal His 6 tag and purified them on Ni-NTA-agarose. Purified cSENPs were incubated with HA-SUMO1-VS or HA-SUMO2-VS, and reactivity was monitored by following adduct formation using SDS/PAGE and protein staining (Figures 2A-2E ). Both cSENP1 ( Figure 2A ) and cSENP2 ( Figure 2B ) were efficiently labelled with SUMO1-VS and SUMO2-VS, suggesting that they recognize and bind SUMO and are potentially active with both SUMO1 and Kinetic parameters of cSENP catalytic activity (k cat , K m and k cat /K m values) were determined using SUMO-AMC hydrolysis assay for each substrate [45] . Experiments were performed in triplicate and the resulting data were fitted to a Michaelis-Menten equation. As reported previously [16] , expression of cSENP3 in E. coli is poor and results in an unstable protein preparation (results not shown). Thus we could not test the SUMO-VS reaction with this protein using direct protein staining. As a result, we verified adduct formation by Western blotting of a lysate from E. coli cells expressing FLAG-tagged cSENP3. A fraction of cSENP3 formed adducts with each SUMO-VS reagent ( Figure 2F , upper panel). The higher-molecular-mass bands detected in the presence of SUMO-VS are reactive with anti-FLAG antibody, but did not form when the catalytic cysteine residue was mutated to alanine ( Figure 2F , lower panel).
Thus these data demonstrate that cSENPs 1, 2, 3, 5, 6 and 7 all can form adducts with SUMO1-VS and SUMO2-VS, but there is little evidence of specificity among the SUMO paralogues. However, labelling with SUMO-VS reagents is irreversible and rapid, and the above results reflect a combination of binding and catalytic capability rather than kinetic preferences.
Steady-state kinetics of SUMO-AMC hydrolysis by the cSENPs
To separately determine the binding and catalytic preferences of cSENPs, we used SUMO-AMC substrates and measured various catalytic parameters (Table 1 and Supplementary Figure S2 at http://www.BiochemJ.org/bj/430/bj4300335add.htm). Catalytic rates (k cat ) vary approx. 100-fold, with the highest rate being 10 −2 s −1 . Catalytic efficiency (k cat /K m ) varies 1000-fold, with the highest rate (2.3 × 10 6 M −1 · s −1 ) approaching the protein-protein diffusion limit. cSENP1 exhibits K m values of 15 nM for SUMO1-AMC and 40 nM for SUMO2-AMC, whereas the K m values for cSENP2 are in the range 20-30 nM. Thus cSENP1 and cSENP2 exhibit similar kinetic affinities for both SUMO paralogues. As shown in Figure 3 , the ratio of paralogue-specific k cat (maximal rate of catalysis) and k cat /K m (catalytic efficiency) indicate that cSENP1 and cSENP2 have no marked catalytic preference for either SUMO paralogue.
In the case of cSENP5 and cSENP6, the K m values for SUMO1-AMC are in the range 150-180 nM, whereas the K m values for SUMO2-AMC are 50-100 nM. These data reflect a similar kinetic affinity of cSENP5 and cSENP6 for SUMO1 and SUMO2 (Table 1 ). The ratio of paralogue-specific kinetic constants for cSENP5 and cSENP6 indicate a marked catalytic preference for SUMO2 (Figure 3) . k cat /K m measurements show that cSENP5 and cSENP6 are approx. 30-fold more selective for SUMO2 than for SUMO1. The activity of cSENP7 on SUMO1-AMC was undetectable, suggesting that SENP7 cannot catalyse hydrolysis of SUMO1.
Binding of SUMO to cSENPs
To unambiguously determine the binding constants for each SUMO paralogue, we measured the K i values for inhibition of SUMO-AMC cleavage by free SUMO paralogues. We determined inhibition constants by conducting kinetic studies in the presence of various amounts of SUMO1 or SUMO2 (Table 2) . With the exception of cSENP7, all cSENPs bound both substrates with affinities (K i values) between 10 and 100 nM. The K i /K m ratios for cSENPs 1 and 2, and 5 and 6 are close to 1, for both SUMO1 and SUMO2. This suggests that catalysis is the ratelimiting step for these SENPs. The only exception was cSENP7, where both the K i value and the K i /K m ratio are at least 10-fold higher than for the other cSENPs. In general, K i is a direct measure of the binding constant for free enzyme binding to the product, SUMO, whereas K m is a complex kinetic term that represents the concentration of substrate necessary to achieve half-maximal Table 2 Binding constants of cSENPs for SUMO paralogues
The affinity of cSENPs for SUMO paralogues was determined by measuring the K i for competitive inhibition of hydrolysis of SUMO1-AMC and SUMO2-AMC by the addition of free SUMO1 or SUMO2. concentration of the species preceding the rate-limiting step. The finding of a K i /K m ratio of 10 suggests that either AMC contributes to the strength of substrate binding or that a step subsequent to formation of the acyl enzyme and release of AMC is rate-limiting for SENP7 (see the Discussion).
SUMO paralogue specificity of cellular SENPs
To characterize the paralogue specificity of full-length SENPs in cell lysates, we utilized SUMO-VS. The specificity of these reagents was confirmed using a well-characterized yeast protease, Ulp1, known to deSUMOylate proteins modified by both SUMO1 and Smt3 [48] . High-molecular-mass adducts resulted from the covalent modification of the active cysteine residue on Ulp1 with both SUMO-VS paralogues (see Supplementary Figure  S3 at http://www.BiochemJ.org/bj/430/bj4300335add.htm). To confirm that this reaction is SUMO-specific, we performed this experiment with similar derivatives of ubiquitin and the ubiquitinlike proteins HA-NEDD8-VS and HA-ISG15 (interferonstimulated gene 15)-VS. Adducts were formed only in the presence of SUMO1-VS or SUMO2-VS (Supplementary Figure  S3) , confirming that these reagents are target-specific and react with Ulp1. The catalytic domain of Ulp1 (His 6 -Ulp1 403−621 ) also reacts with both SUMO1-VS and SUMO2-VS (results not shown). In separate experiments, ubiquitin-VS, NEDD8-VS and ISG15-VS were tested with their respective optimal enzymes Uchl3, Den1 and Ubp43 and were found to be fully functional [25, 44, 49] . Thus, in accordance with these results and those of others [4, 23, 42, 46, 47] , reactivity with SUMO-VS preferentially (probably exclusively) detects SUMO-specific enzymes.
We next treated a HEK-293 cell lysate (30 μg) with increasing amounts of HA-SUMO2-VS and monitored SENP3 adduct formation using anti-SENP3 antibodies ( Figure 4A) . A gel shift was observed with increasing amounts of HA-SUMO2-VS. Complete conversion of free SENP3 into an adduct confirms that all detectable endogenous SENP3 reacts with SUMO2-VS. We performed similar experiments using anti-SENP5 antibody with similar results ( Figure 4B ). We could estimate the amount of SENPs present in a lysate by noting the minimum amount of SUMO-VS necessary to consume all of the free SENPs ( Figures 4A and 4B) . On the basis of the minimum amount of SUMO-VS required to react with all of the SENPs in these titrations, and an average molecular mass of the SUMO-VS adducts formed of ∼ 10 5 Da, we estimate that no more than approx. 0.06 % of the lysate protein are SENPs.
The selectivity of cellular SENPs was compared by incubating HeLa cell lysates with either HA-SUMO1-VS or HA-SUMO2-VS and used specific polyclonal antibodies prepared against each full-length protease to determine the pattern of adduct formation for each endogenously expressed SENP (Figures 4C-4H) . Endogenous SENPs 2, 3, 5, 6 and 7 showed preferential reactivity with SUMO2. In contrast, endogenous SENP1 formed highermolecular-mass adducts with both SUMO1-VS and SUMO2-VS ( Figure 4C ). Multiple bands were detected with most of these antibodies and we do not know whether all of these bands represent the respective SENPs. However, we can say that at least some of these bands are shifted and that this probably indicates the specificity of the indicated SENP. Unshifted bands may be other cross-reactive proteins or may represent catalytically inactive protein due to partial denaturation or covalent modification.
As expected, cSENP1 ( Figure 2A ) and endogenous fulllength SENP1 ( Figure 4C ) formed adducts with HA-SUMO1-VS and HA-SUMO2-VS. cSENP2 reacted with HA-SUMO1-VS ( Figure 2B ), but endogenous SENP2 did not ( Figure 4D ). The main difference between cSENP and endogenous SENP is that the endogenous protein contains the N-terminal domain and any potential post-translational modifications. In general, the N-terminal domain is projected to play regulatory roles in vivo, including contributions to substrate specificity and protein localization [15, 29] . To explore whether the N-terminal domain of SENP2 modulates its catalytic specificity, we expressed full-length His 6 -SENP1 and full-length His 6 -SENP2 in E. coli. Homogenates were incubated with HA-SUMO1-VS or HA-SUMO2-VS, and adduct formation was confirmed by immunoblotting with anti-HA antibody. Similar to the pattern with endogenous proteins, His 6 -SENP1 reacted with both SUMO1-VS and SUMO2-VS ( Figure 5 ), whereas His 6 -SENP2 reacted only weakly with SUMO1-VS ( Figure 5 ). Thus full-length recombinant His 6 -SENP2 exhibits paralogue selectivity similar to that of endogenous SENP2, suggesting that the N-terminal domain may contribute to substrate specificity. The presence of bands at molecular masses lower than those of fulllength His 6 -SENP1 and His 6 -SENP2 suggests limited proteolysis of the recombinant proteins. We were unable to perform detailed kinetic studies with full-length SENP1 and SENP2 due to the instability of these protein preparations (results not shown).
Labelling of SENPs in mammalian cells and tissue extracts
We also tested formation of adducts between SUMO-VS and SENPs in lysates of other cells to compare the specificity of deSUMOylation with that revealed by the kinetic measurements and the labelling experiments with HeLa cells (Figure 4) .
We examined endogenous SENP selectivity by testing lysates from a panel of mammalian cells: HeLa, Cos7, HEK-293, LM TK − and A9. Proteins labelled with the HA-SUMO-VS reagents were detected by Western blotting with an anti-HA antibody ( Figure 6 ). We found that most cell lines appear to form an adduct of approx. 90-100 kDa with SUMO1-VS. Given the specificity of cSENPs and the apparent molecular mass of the observed adduct, it is likely that this band represents SENP1 labelled irreversibly with SUMO1-VS. However, on the basis of molecular mass alone, this band could also correspond to SENP2 or SENP5. In the case of SUMO2-VS, we detected corresponding adducts of various molecular masses, indicating the possible labelling of SENP 2, 3, 5, 6 or 7 ( Figure 6 ). In the HeLa cell lysate labelled with SUMO2-VS, these shifted bands correspond to SENPs 1, 2, 3, 5, 6 and 7 when probed with anti-SENP antibodies respectively ( Figures 4C-4H) .
Finally, we prepared tissue extracts from rabbit thymus, spleen, heart, brain, adrenal and thyroid glands to examine the distribution of active SENPs using the SUMO-VS reagents ( Figure 7 and results not shown). An anti-HA antibody was used to analyse SENP labelling patterns as described above. The thymus, in particular, contains a significant amount of SENPs that formed adducts with SUMO2-VS ( Figure 7 , lane 3, and Supplementary Figure S4 at http://www.BiochemJ.org/bj/ 430/bj4300335add.htm). SUMO2-VS adducts are also observed in the spleen and adrenal gland lysates. However, the SENP protein levels in these lysates appear to be low and yield low levels of adducts, particularly for the SUMO1-VS reagent. Little significant SENP labelling was seen in brain or heart (results not shown). Rabbit tissue extracts could not be probed with the available anti-SENP antibodies, as they were all raised in rabbits. 
Catalytic capability of tissues and cell lysates
To examine the balance of cellular activities acting upon SUMO1 and SUMO2, we measured the ability of these endogenous SENPs present in cell and tissue lysates to hydrolyse SUMO1-AMC or SUMO2-AMC (Table 3) . We first characterized the SUMO1-AMC and SUMO2-AMC substrates by incubating with a panel of enzymes with selectivity for different ubiquitin-like proteins: GST (glutathione transferase)-Ulp1 and His 6 -Ulp1 403−621 (SUMOspecific), Uchl3 (ubiquitin-selective), Den1 (NEDD8-selective) and Ubp43 (ISG15-specific). Hydrolysis was detected by an increase in fluorescence due to the release of AMC. As expected, SUMO1-AMC and SUMO2-AMC were only hydrolysed by GST-Ulp1 and His 6 -Ulp1 403−621 and not by ubiquitin-, NEDD8-or ISG15-specific enzymes (results not shown), demonstrating that these substrates can be used to specifically detect deSUMOylating enzyme activity in crude extracts.
The levels of SUMO1-AMC and SUMO2-AMC hydrolysis seen in cell and tissue lysates (Table 3) suggest that most contain active SENPs capable of hydrolysing SUMO-AMC. Consistent with the adduct formation data, SUMO2-AMC is hydrolysed more readily (12-20-fold faster) than SUMO1-AMC, indicating that SUMO2-modified substrates are more likely to be processed in cells and tissues. Thymus and spleen are the richest source of SENPs, whereas brain and heart exhibit very low levels. This may suggest that deSUMOylation is more important in proliferating cells.
DISCUSSION

SENP1 is unique in its propensity to act efficiently on both SUMO1 and SUMO2
Previous biochemical studies suggest that SENP1 is a major SENP for processing and deconjugating SUMO1 [50] and is the most common SUMO-endopeptidase in the cell [16, 21] . It forms adducts with SUMO1-VS [23, 46] and the residues responsible for the SUMO1-SENP1 association are known [20, 50, 51] . We confirmed that endogenous SENPs in cell lysates react with SUMO-VS, giving at least one adduct with an approximate molecular mass of 100 kDa (Figure 6 ), consistent with an irreversible association of SUMO1-VS with SENP1. We verified this result using anti-SENP1 antibodies in HeLa cell lysates, and confirmed our hypothesis that endogenous SENP1 can associate with both SUMO1-VS and SUMO2-VS ( Figure 4C) .
A detailed study of the kinetics, structure and molecular mechanisms of the SENP1 catalytic domain suggests that it has a high affinity for SUMO and physiologically relevant substrates (RanGAP1-SUMO1), and lesser affinities for YFP (yellow fluorescent protein)-SUMO-CFP (cyan fluorescent protein) fusion proteins [50] . We also observed high affinities for SUMO binding to cSENP1, with there being a slight preference for binding to SUMO1 ( Table 2 ). The absolute values for binding of SUMO by cSENP1 measured by ITC (isothermal titration calorimetry) [50] or kinetic inhibition (Table 2 ) agree to within an order of magnitude. Thus there is little discrimination by cSENP1 for SUMO paralogues with non-physiological leaving groups on the basis of their binding preferences. K m values of 15 nM for SUMO1-AMC and 40 nM for SUMO2-AMC are slightly lower than those reported previously for SUMO paralogues bearing nonphysiological leaving groups [50] . The apparent K m for cSENP1-catalysed hydrolysis of YFP-SUMO1-CFP and YFP-SUMO2-CFP substrates is 98 and 126 nM respectively, values that are similar to the binding constants measured by ITC. The similarity of K i and K m values for non-physiological substrates argues that the rate-limiting step for these substrates is acyl enzyme formation. With a physiological substrate, SUMO1-RanGAP1, cSENP1 exhibits a K m that is 15-fold higher than the binding affinity [50] , arguing that release of RanGAP1 is much slower and at least partially rate-limiting. This is consistent with the presence of weak interactions between RanGAP1 and both SUMO1 and cSENP1 observed in the crystal structure of the cSENP1(C603A)-RanGAP1-SUMO1 complex [50] .
The catalytic rate (k cat ) for different paralogues differs only 2-fold for SUMO-AMC and SUMO-RanGAP1, but is 50-fold higher for cSENP1 acting on YFP-SUMO1-CFP compared with YFP-SUMO2-CFP. These differences are likely to be due to differences in substrate structure and orientation of the scissile bond. We find that when the leaving group is AMC, cSENP1 shows very similar kinetics for the hydrolysis reaction of either SUMO1 or SUMO2, as indicated by k cat /K m ratios and k cat values (Table 1) . We also observe lower k cat rates than those observed previously for cSENP1 acting on YFP-SUMO1-CFP [50] . This discrepancy may be due to suboptimal geometry at the scissile bond [52] , the nature of the AMC group or differences in the assay formats. We note, however, that k cat /K m values reported for SUMO-RanGAP1 substrates are in excess of 10 9 M −1 · s −1 , values that greatly exceed the diffusion limit. It remains to be seen whether those values can be confirmed. Nonetheless, our data, and those of others, clearly suggest that full-length SENP1 is a major endogenous SENP, and has a unique capability of effectively working on both SUMO1 and SUMO2 conjugates ( Figures 4C and 5A ) not shared by other SENPs.
Previous studies have indicated that the major organ for SENP1 protein expression is in the testis, with detectable levels in thymus, pancreas, spleen, liver, ovary and small intestine, and does not vary greatly for other SENPs [21] . We observed little adduct formation in tissue extracts after incubation with SUMO1-VS (Figure 7) , suggesting that levels of SUMO1-specific SENPs are relatively low in tissues. This is confirmed by measurements of the rates of hydrolysis of SUMO1 and SUMO2-AMC in tissues and cell extracts (Table 3 and Supplementary Figure S4) . Labelling with SUMO2-VS in rabbit thymus lysates shows a 100 kDa band that may be indicative of SENP1 or SENP2 (by molecular mass). The lower band of approx. 70 kDa seen in thymus, spleen and adrenal tissue may be non-specific association with the VS reagents or a splice variant of an unidentified SENP.
SENP2 requires its N-terminal domain to regulate SUMO paralogue specificity
cSENP2 reacted with SUMO1-VS, whereas endogenous SENP2 in cell lysates reacted only weakly. SUMO-VS labelling experiments using lysates suggest that the N-terminal domain of SENP2 may exert a significant degree of regulation over the catalytic domain ( Figure 4D ). Nonetheless, we tested the ability of recombinant full-length SENP1 and SENP2 to react with SUMO1-VS or SUMO2-VS. As seen with endogenous SENP1 and SENP2 (Figures 4C and 4D) , recombinant full-length SENP2 irreversibly reacts readily with SUMO2-VS, but only weakly with SUMO1-VS, whereas SENP1 reacts with both ( Figure 5) .
In the present study, cSENP1, cSENP2 and full-length SENP1 do not show a preference for SUMO paralogues in labelling with SUMO-VS or hydrolysis of SUMO-AMC. However, fulllength SENP2, differing from cSENP2 only in the presence of the N-terminal sequence, exhibits a clear paralogue specificity for SUMO2 over SUMO1. cSENP2 catalyses hydrolysis of SUMO1-AMC and SUMO2-AMC with K m values of 30 and 20 nM respectively and similar k cat values (Table 1) . Previous studies have shown similar k cat values for both SUMO paralogues, but their apparent K m was lower for RanGAP1-SUMO2 than for RanGAP1-SUMO1 [52] . Again, this discrepancy may be due to the nature of the AMC group, or differences in the assay formats. Full-length recombinant protein containing the N-terminal sequence is somewhat unstable and is not appropriate for detailed kinetic measurements (results not shown). The N-terminal domain of SENP2 has an NLS and a NES that facilitates movements between nucleus and cytoplasm [39] . In addition, the N-terminal domain of SENP2 is responsible for associating with the nuclear pore [32, 33] , but it has not been implicated directly in specificity for different SUMO paralogues. Since SENP1 and SENP2 have differences in the N-terminus, they may also display differences in localization and substrate binding. Therefore the N-terminal domains of SENPs could play an important role in direct recognition of substrates either by restricting or allowing access to the catalytic domain or by the action of scaffolds or adaptors for co-localization.
SENP3 and SENP5 show a strong preference for SUMO2
cSENP3 and endogenous SENP3 bound SUMO2-VS irreversibly, but not SUMO1-VS, indicating a very specific recognition ( Figures 2F, 4A and 4E ). SENP3 is abundant in HeLa cells, in Xenopus laevis extracts, and in thymus and spleen tissues in humans [4, 47] . Since it is well established that SENP3 binds SUMO2-modified nucleophosmin through the N-terminal region and displays specificity for SUMO2 and SUMO3 conjugates [4, 40, 43] , it is likely that SENP3 plays a role in SUMO2/3 metabolism. Although we did not obtain detailed catalytic measurements for cSENP3, we detected a similar pattern of selectivity to that observed for cSENP5.
Figure 2(C) shows that cSENP5 reacts with SUMO1-VS and Table 2 indicates a K m of 180 nM for SUMO1-AMC. Nevertheless, Figure 4 (F) suggests that endogenous SENP5 only reacts with SUMO2-VS and not SUMO1-VS. Because cSENP5 exhibits a K m of 50 nM for SUMO2-AMC, it appears that SENP5 is more likely to process SUMO2/3 than SUMO1, as suggested previously [22, 42] . Similarly, k cat /K m measurements revealed cSENP5 to be 10-fold more active on SUMO2 than SUMO1 ( Figure 3 and Table 2 ).
These data do not negate the possibility that SENP5 may process SUMO1 in vivo, in particular because the catalytic domain of SENP5 catalyses AMC hydrolysis from SUMO1 with a k cat that is only 4-fold lower than cSENP1 (Table 1) and it has been reported to deconjugate SUMO1 from PML [22] . Additionally, an increase in the levels of SUMO1 is observed when SENP3 and SENP5 are co-depleted from the cell [4] , suggesting that these enzymes may play an indirect role in SUMO1 metabolism that has yet to be determined. One can speculate that if the enzyme were localized near the substrate through the actions of an adapter or scaffold, it has sufficient catalytic capability to act upon that substrate. Further study is required to investigate the roles for SENP5 regarding SUMO1 deconjugation and processing.
The SENP6 and SENP7 family
Interestingly, both the SENP6 catalytic domain and endogenous SENP6 have a high catalytic selectivity for SUMO2 and specific reaction with SUMO2-VS ( Figures 1D and 3G) . We found that SENP6 has K m values of 145 and 100 nM for SUMO1-AMC and SUMO2-AMC respectively. Thus SENP6 may be mostly involved in SUMO2/3 pathway regulation, especially in the light of evidence that it preferentially acts on substrates containing three or more SUMO2/3 moieties [23] . Both cSENP6 and cSENP7 have higher isopeptidase activity, cleave SUMO2 from RanGAP1, but not SUMO1 [16, 24, 53] , and preferentially catalyse di-SUMO2 and poly-SUMO2/3 deconjugation [23, 24, 53] .
Although our cSENP7 protein preparation was of somewhat lower yield [16] , we were still able to perform kinetic analyses and determined a K m of 80 nM for SUMO2-AMC. cSENP7 did not hydrolyse SUMO1-AMC (Table 1) , but reacted irreversibly with SUMO1-VS ( Figure 2E) . Apparently, the cSENP7-SUMO1 association is of low affinity and the leaving group in SUMO1-AMC may not be accessible for hydrolysis. We find that cSENP7 reacts weakly with both SUMO-VS derivatives forming the respective adducts, but endogenous SENP7 reacts only with SUMO2-VS ( Figure 4H ). These data are indicative of a role for SENP7 in SUMO2-related pathways. However, caveats include that cSENP7 may require the N-terminal domain to function properly and that specificity or stability may depend on posttranslational modifications. The absence of the N-terminal α-helix from the cSENP7 crystal structure (that is present in SENP1 and SENP2 structures) may also relate to its unique function [53] .
SENP specificity and catalysis
Catalysis is an inherent property of cSENPs, as indicated by kinetic data outlined in Table 1 . All cSENPs, with the exception of cSENP7, catalysed both SUMO1-AMC and SUMO2-AMC hydrolysis with K m values in the nanomolar range. Specificity was evident in the kinetic studies of all the cSENPs: cSENP1 has a higher activity on SUMO1 and cSENPs 2, 5, 6 and 7 have higher activity on SUMO2 (Table 2 ). These preferences are largely due to differences in catalytic efficiencies and not the ability to bind either SUMO paralogue. Thus all cSENPs reacted with both SUMO1-VS and SUMO2-VS (Figure 2) Specificity is likely to be achieved as a result of modulating the rates of acyl enzyme formation and release of the leaving group. SENPs catalyse a Ping Pong Bi Bi mechanism with water as the second substrate. At constant concentrations of water, this becomes an ordered Uni Bi mechanism where S = SUMO-AMC, P = AMC and Q = SUMO, and E Q is the acyl enzyme [54] :
Under initial rate conditions, P approaches 0 and k 2 (acylation of the SENP with release of AMC) becomes the first irreversible step.
For this model,
and
When K i = K m for SUMO, as is the case for SENPs 1, 2, 5 and 6, the simplest explanation is that k 1 /k −1 = k −4 /k 4 ; i.e. the influence of the AMC moiety on substrate binding is minimal and acylation (k 2 ) is the rate-limiting step. The identity of the SUMO paralogue and the leaving group would both be expected to strongly influence this rate, imparting specificity to catalysis.
When K i K m , there are two options: either the presence of a leaving group (AMC in our case) enhances substrate binding (k 1 /k −1 k −4 /k 4 ) or the equilibrium for substrate binding is pulled by additional downstream equilibria preceding a ratelimiting step subsequent to acylation [54] . The subsequent steps involve hydrolysis of the acyl enzyme and release of SUMO, and this step is identical regardless of the identity of the leaving group. The net rate at which the acyl enzyme is hydrolysed and SUMO released is k 3 k 4 /(k −3 + k 4 ). To distinguish between these mechanistic alternatives requires measurement of the corresponding parameters using substrates with alternative leaving groups. Previous studies showed that SENP7 has a preference for cleavage of SUMO2 derivatives [7, [55] [56] [57] [58] . This same study provides estimates of the catalytic efficiency of SENP7 catalysing the hydrolysis of di-SUMO2 (∼ 0.2 s −1 ), SUMO2-RanGAP1 (0.02 s −1 ) and SUMO2 pro-protein (<10 −4 s −1 ). We find a rate for SUMO2-AMC hydrolysis of 2 × 10 −4 s −1 , consistent with these measurements. However, these studies make it clear that the rate of deacylation and SUMO release must exceed 0.2 s −1 and cannot be rate-limiting in our studies. Thus it is likely that the AMC leaving group makes favourable interactions with the substrate-binding site and is bound much more tightly than is free SUMO2. It is possible that the additional sequence interrupting the core catalytic domain contributes to this interaction with AMC and reflects additional interaction surfaces used in recognizing poly-SUMO2/3.
SUMO2/3 metabolism is more dynamic than that of SUMO1 in lysates
When we performed labelling experiments with SUMO-VS using cell lysates, we observed a higher concentration of proteins that form adducts with SUMO2-VS than with SUMO1-VS ( Figures 4C-4H ). On the basis of the molecular mass shifts observed upon reaction with SUMO-VS and anti-SENP antibodies (Figure 4) , we believe that endogenous SENPs 2, 3, 5, 6 and 7 in cells and tissues preferentially react with SUMO2-VS. SUMO1/2-AMC substrates were both efficiently hydrolysed by mammalian cell lysates and rabbit tissue extracts (Table 3) . However, in all tissues and cell lysates examined, there was a 15-20-fold higher activity on SUMO2-AMC than activity on SUMO1-AMC (Table 3) . Thus, by both criteria, there is much more capacity for SUMO2 metabolism than for SUMO1.
The total amount of SUMO2/3 in the cell is greater than that of SUMO1 [12] , and the rapidity of response to stress [7, [55] [56] [57] [58] implies that there is a dynamic equilibrium between SUMOylation and deSUMOylation processes. Depletion of SENPs 1, 2, 3, 5, 6 and 7 causes a dramatic increase in higher-molecularmass conjugates [4, 23, 24, 42, 43] . These observations suggest a higher degree of SUMO2/3 dynamics in the cellular environment supporting an active role for SENP enzymes in regulatory processes.
The present systematic analysis of mammalian SENPs 1, 2, 3, 5, 6 and 7 supports a strong preference for SUMO2/3 relative to SUMO1. Furthermore, our studies clearly indicate a role for the divergent N-terminus of SENPs in restricting activity on many SUMO substrates in vivo. The mechanisms of this regulation is most likely through localization, physical interaction with a SUMO-modified substrate, or binding to an adapter that delivers and/or helps to reorient the substrate cleavage site.
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